A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Acronyms SAHARA
- Sponsors Shire; ViroPharma Incorporated
- 01 Sep 2017 Status changed from active, no longer recruiting to completed.
- 14 Jun 2017 This trial has been completed in Spain.
- 10 Jun 2017 Biomarkers information updated